OZONO Yoshinori



Faculty of Medicine College Hospital Department of Gastroenterology


Assistant Professor

External Link

Degree 【 display / non-display

  • 博士(医学) ( 2021.3   宮崎大学 )


Papers 【 display / non-display

  • Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Reviewed International journal

    Yoshinori Ozono, Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Yuki Tahira, Masaaki Sekine, Keiichi Akizuki, Kenichi Nakamura, Hisayoshi Iwakiri, Mitsue Sueta, Tomonori Hidaka, Yoko Kubuki, Shojiro Yamamoto, Satoru Hasuike, Akira Sawaguchi, Kenji Nagata, Kazuya Shimoda

    Leukemia   35 ( 2 )   454 - 467   2021.2

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

    Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by clonal myeloproliferation, progressive bone marrow (BM) fibrosis, splenomegaly, and anemia. BM fibrosis was previously thought to be a reactive phenomenon induced by mesenchymal stromal cells that are stimulated by the overproduction of cytokines such as transforming growth factor (TGF)-β1. However, the involvement of neoplastic fibrocytes in BM fibrosis was recently reported. In this study, we showed that the vast majority of collagen- and fibronectin-producing cells in the BM and spleens of Jak2V617F-induced myelofibrosis (MF) mice were fibrocytes derived from neoplastic hematopoietic cells. Neoplastic monocyte depletion eliminated collagen- and fibronectin-producing fibrocytes in BM and spleen, and ameliorated most characteristic MF features in Jak2V617F transgenic mice, including BM fibrosis, anemia, and splenomegaly, while had little effect on the elevated numbers of megakaryocytes and stem cells in BM, and leukothrombocytosis in peripheral blood. TGF-β1, which was produced by hematopoietic cells including fibrocytes, promoted the differentiation of neoplastic monocytes to fibrocytes, and elevated plasma TGF-β1 levels were normalized by monocyte depletion. Collectively, our data suggest that neoplastic fibrocytes are the major contributor to BM fibrosis in PMF, and TGF-β1 is required for their differentiation.

    DOI: 10.1038/s41375-020-0880-3




  • Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1 Reviewed

    Ozono Y., Nagata K., Hasuike S., Iwakiri H., Nakamura K., Tsuchimochi M., Yamada Y., Takaishi Y., Sueta M., Miike T., Tahara Y., Yamamoto S., Shide K., Hidaka T., Kubuki Y., Kusumoto K., Ochiai T., Kato J., Komada N., Hirono S., Kuroki K., Shigehira M., Shimoda K.

    World Journal of Hepatology   9 ( 36 )   1340 - 1345   2017.12

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:World Journal of Hepatology  

    AIM To evaluate the efficacy and safety of a regimen containing sofosbuvir (SOF) and ledipasvir (LDV) in Japanese patients aged ≥ 75 years with hepatitis C genotype 1. METHODS This multicenter, retrospective study consisted of 246 Japanese patients with HCV genotype 1 at nine centers in Miyazaki prefecture in Japan. Demographic, clinical, virological, and adverse effects (AE)-related data obtained during and after SOF/LDV therapy were collected from medical records. These patients were divided into two groups, younger (aged < 75 years) and elderly (aged ≥ 75 years). Virological data and AEs were analyzed by age group. RESULTS The sustained virological response (SVR) rates at 12 wk after treatment were 99.2%, 99.4%, and 98.7% in the overall population and in patients aged < 75 and ≥ 75 years, respectively. Common AEs during therapy were headache, pruritus, constipation, and insomnia. These occurred in fewer than 10% of patients, and their incidence was not significantly different between the younger and elderly groups. Two patients discontinued treatment, one due to a skin eruption and the other due to cerebral bleeding. CONCLUSION Compared with younger patients, elderly patients had a similar virological response and tolerance to SOF/LDV therapy.

    DOI: 10.4254/wjh.v9.i36.1340



  • Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report. Reviewed

    Uchida K, Ozono Y, Uchiyama N, Hatada H, Nakamura K, Komaki Y, Iwakiri H, Hasuike S, Nagata K, Sato Y, Kawakami H

    Medicine   101 ( 35 )   e30486   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/MD.0000000000030486


  • 特集 胆道ドレナージのすべて-適応・方法 2.各論(7)経皮的胆囊ドレナージ

    河上 洋, 畑田 紘志, 内山 尚美, 小川 宗一郎, 田村 穂高, 大園 芳範

    臨床消化器内科   37 ( 10 )   1342 - 1349   2022.8

     More details

    Publishing type:Research paper (scientific journal)   Publisher:日本メディカルセンター  

    DOI: 10.19020/cg.0000002361

    CiNii Research

  • Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency. Reviewed

    Hotaka Tamura, Koji Nakashima, Naomi Uchiyama, Souichiro Ogawa, Hiroshi Hatada, Naoki Yoshida, Keisuke Uchida, Yoshinori Ozono, Hiroyuki Tanaka, Koji Yamamto, Hiroshi Kawakami

    Internal medicine (Tokyo, Japan)   61 ( 10 )   1503 - 1509   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    DOI: 10.2169/internalmedicine.8254-21


    CiNii Research


display all >>

Grant-in-Aid for Scientific Research 【 display / non-display

  • 肝硬変、NASH発症・進展に果たす造血細胞の関与の解明と新たな治療標的の確立

    Grant number:19K17404  2019.04 - 2022.03

    科学研究費補助金  若手研究

      More details

    Authorship:Principal investigator